Publications

Add filters (0)

16 results

Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development – Should future studies focus on disease activity, rather than status?

September 1, 2022

Osteoarthr Cartil Open

Abstract OBJECTIVE Osteoarthritis (OA) is heterogeneous disease, for which drug development has proven to be challenging, both facilitated and hampered by changing guidelines. This is evident by the current lack of approved treatments, which improve joint function and delay joint failure. There is a need to bring together key stakeholders to discuss, align and enhance […]

Read publication

A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis.

December 1, 2021

Osteoarthr Cartil Open

Abstract OBJECTIVES There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and discusses its potential as a noninvasive translational biomarker. METHODS A type II collagen specific neoepitope […]

Read publication

Development of a highly sensitive chemiluminescence immunoassay for quantification of aggrecanase-generated ARGS aggrecan fragments in serum.

June 1, 2021

Osteoarthr Cartil Open

Abstract OBJECTIVE Cartilage degradation is a hallmark of osteoarthritis (OA). Aggrecan, a major proteoglycan of articular cartilage extracellular matrix (ECM), is degraded by ADAMTS-5 resulting in the release of ARGS-G2 fragments to synovial fluid and circulation. The aim was to quantify ARGS-G2 in the serum of OA patients using the huARGS immunoassay. METHODS The immunoassay […]

Read publication

Colony housing promotes structural and functional changes during surgically induced osteoarthritis in rats.

December 1, 2020

Osteoarthr Cartil Open

Abstract OBJECTIVE The aim of the study was to investigate how social housing with high locomotion activity affects experimental osteoarthritis (OA) in rats. DESIGN Rats were housed either conventionally in type IV cages in pairs or in rat colony cages (RCC) on 4 levels interconnected by jump holes or staircase in groups of 48. OA […]

Read publication

Serological CTX-II does not measure the same as urinary CTX-II.

September 1, 2020

Osteoarthr Cartil Open

Abstract OBJECTIVE Type II collagen is the most abundant protein of articular cartilage. The urinary cross-linked C-terminal telopeptide of type II collagen (uCTX-II) is a matrix metalloproteinase (MMP) cleaved fragment and may be the most well-validated biomarker in osteoarthritis. The aim was to develop a serological immunoassay of CTX-II (sCTX-II) and evaluated both sCTX-II and […]

Read publication

Evaluation of serum ARGS neoepitope as an osteoarthritis biomarker using a standardized model for exercise-induced cartilage extra cellular matrix turnover.

June 1, 2020

Osteoarthr Cartil Open

Abstract OBJECTIVE To propose a standardized model for exercise-induced cartilage turnover and investigate residual levels and dynamics of biomarker serum ARGS (sARGS) in primary osteoarthritis (OA) patients and a supportive group of young healthy subjects. METHOD The trial is a randomized, cross-over, exploratory study with interventions of exercise and inactivity. 20 subjects with knee OA, […]

Read publication